exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
Company profile
Ticker
EXAS
Exchange
Website
CEO
Kevin Conroy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EXACT CORP
SEC CIK
Corporate docs
Subsidiaries
Genomic Health, Inc. • Exact Sciences Laboratories, LLC • Exact Sciences Thrive, LLC ...
IRS number
204782291
EXAS stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
21 Feb 24
8-K
Exact Sciences Announces Fourth Quarter 2023 Results
21 Feb 24
8-K
Exact Sciences Announces Preliminary Fourth Quarter 2023 Results
8 Jan 24
10-Q
2023 Q1
Quarterly report
1 Nov 23
8-K
Exact Sciences Announces Third-Quarter 2023 Results Reports record revenue, delivers more than a million test results, raises full-year guidance
1 Nov 23
10-Q
2023 Q1
Quarterly report
1 Aug 23
S-8
Registration of securities for employees
1 Aug 23
8-K
Exact Sciences Announces Second-Quarter 2023 Results Reports record results, generates positive free cash flow, raises full-year guidance
1 Aug 23
8-K
Regulation FD Disclosure
21 Jun 23
8-K
Material Modifications to Rights of Security Holders
12 Jun 23
Transcripts
EXAS
Earnings call transcript
2023 Q4
21 Feb 24
EXAS
Earnings call transcript
2023 Q3
1 Nov 23
EXAS
Earnings call transcript
2023 Q2
1 Aug 23
EXAS
Earnings call transcript
2023 Q1
9 May 23
EXAS
Earnings call transcript
2022 Q4
21 Feb 23
EXAS
Earnings call transcript
2022 Q3
4 Nov 22
EXAS
Earnings call transcript
2022 Q2
2 Aug 22
EXAS
Earnings call transcript
2022 Q1
27 Apr 22
EXAS
Earnings call transcript
2021 Q4
23 Feb 22
EXAS
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
144
Notice of proposed sale of securities
28 Mar 24
4
JACOB A ORVILLE
4 Mar 24
4
DANIEL J LEVANGIE
4 Mar 24
4
James Herriott
4 Mar 24
4
Jeffrey Thomas Elliott
4 Mar 24
4
James Edward Doyle
4 Mar 24
4
Everett Cunningham
4 Mar 24
4
Kevin T Conroy
4 Mar 24
4
Sarah Condella
4 Mar 24
4
Brian Baranick
4 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 594.91 mm | 594.91 mm | 594.91 mm | 594.91 mm | 594.91 mm | 594.91 mm |
Cash burn (monthly) | 3.25 mm | (no burn) | (no burn) | 23.34 mm | (no burn) | (no burn) |
Cash used (since last report) | 19.46 mm | n/a | n/a | 139.75 mm | n/a | n/a |
Cash remaining | 575.45 mm | n/a | n/a | 455.16 mm | n/a | n/a |
Runway (months of cash) | 177.0 | n/a | n/a | 19.5 | n/a | n/a |
Institutional ownership, Q3 2023
88.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 604 |
Opened positions | 66 |
Closed positions | 88 |
Increased positions | 224 |
Reduced positions | 196 |
13F shares | Current |
---|---|
Total value | 10.90 tn |
Total shares | 160.23 mm |
Total puts | 1.82 mm |
Total calls | 1.51 mm |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
JPM JPMorgan Chase & Co. | 18.29 mm | $1.25 tn |
Vanguard | 17.44 mm | $1.19 tn |
BLK Blackrock | 11.58 mm | $789.68 bn |
Wellington Management | 10.82 mm | $738.20 bn |
Capital World Investors | 6.93 mm | $472.67 bn |
ARK Investment Management | 6.28 mm | $428.49 bn |
STT State Street | 4.51 mm | $307.71 bn |
Baillie Gifford & Co | 4.07 mm | $277.41 bn |
Artisan Partners Limited Partnership | 3.96 mm | $270.25 bn |
AMP Ameriprise Financial | 3.24 mm | $221.01 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | James Edward Doyle | Common Stock | Sell | Dispose S | No | Yes | 57.5 | 2,000 | 115.00 k | 50,110 |
1 Mar 24 | Levangie Daniel J | Common Stock | Sell | Dispose S | No | Yes | 57.5 | 5,000 | 287.50 k | 22,975 |
1 Mar 24 | Everett Cunningham | Common Stock | Sell | Dispose S | No | Yes | 59.32 | 2,412 | 143.08 k | 46,179 |
1 Mar 24 | Kevin T Conroy | Common Stock | Sell | Dispose S | No | Yes | 59.32 | 8,271 | 490.64 k | 1,299,496 |
1 Mar 24 | Sarah Condella | Common Stock | Sell | Dispose S | No | Yes | 59.32 | 1,724 | 102.27 k | 75,787 |
29 Feb 24 | Everett Cunningham | Common Stock | Option exercise | Acquire M | No | No | 0 | 5,291 | 0.00 | 48,591 |
29 Feb 24 | Everett Cunningham | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 5,291 | 0.00 | 15,876 |
29 Feb 24 | Kevin T Conroy | Common Stock | Option exercise | Acquire M | No | No | 0 | 18,143 | 0.00 | 1,307,767 |
29 Feb 24 | Kevin T Conroy | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 18,143 | 0.00 | 54,429 |
29 Feb 24 | Sarah Condella | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,779 | 0.00 | 77,511 |
News
10 Health Care Stocks Whale Activity In Today's Session
6 Mar 24
10 Health Care Stocks Whale Activity In Today's Session
4 Mar 24
Canaccord Genuity Maintains Buy on Exact Sciences, Lowers Price Target to $90
22 Feb 24
Nasdaq, S&P 500 Futures Jump As Nvidia Surge Raises 'FOMO' Rally Hopes: Analyst Tells Why Jobs Data Holds Key For Momentum
22 Feb 24
Wall Street Waits With Bated Breath For Nvidia Earnings After Tech Selloff, Fed Minutes Eyed: Analyst Flags This As Biggest Risk For Market
21 Feb 24
Press releases
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
28 Mar 24
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
27 Mar 24
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study
13 Mar 24
Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer
7 Mar 24
Exact Sciences to Participate in March Investor Conference
26 Feb 24